Lataa...

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

BACKGROUND: Gemcitabine is used for the treatment of several solid tumours and exhibits high inter-individual pharmacokinetic variability. In this study, we explore possible predictive covariates on drug and metabolite disposition. METHODS: Forty patients were enrolled. Gemcitabine and dFdU concentr...

Täydet tiedot

Tallennettuna:

Bibliografiset tiedot
Päätekijät:	Khatri, A, Williams, B W, Fisher, J, Brundage, R C, Gurvich, V J, Lis, L G, Skubitz, K M, Dudek, A Z, Greeno, E W, Kratzke, R A, Lamba, J K, Kirstein, M N
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Publishing Group 2014
Aiheet:	Clinical Study
Linkit:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3899768/ https://ncbi.nlm.nih.gov/pubmed/24300978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.738
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

Samankaltaisia teoksia